BJINF yields 5.21% · JNJ yields 2.13%● Live data
📍 BJINF pulled ahead of the other in Year 1
Combined, BJINF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BJINF + JNJ for your $10,000?
Beijing Enterprises Holdings Limited, an investment holding company, engages in piped gas, brewery, water and environmental, solid waste treatment, and other businesses in Mainland China and Germany. Its Piped Gas Operation segment distributes and sells piped natural gas and gas-related equipment; provides natural gas transmission services, as well as repair and maintenance services; surveys and plots underground construction projects; and installs gas pipelines and related equipment. The company's Brewery Operation segment produces, distributes, and sells brewery products. Its Water and Environmental segment constructs sewage and water treatment plants and other infrastructural facilities; provides construction services for renovation projects; offers sewage treatment, and water treatment and distribution services, as well as consultancy services; and licenses technical know-how related to sewage treatment. The company's Solid Waste Treatment segment is involved in the construction and operation of waste incineration plants; waste treatment; sale of electricity; generation of heat and stream from waste incineration. Its Corporate and Others segment offers consultation and property investment services. The company also engages in the production and sale of beer; and issue of guaranteed bonds and notes. Beijing Enterprises Holdings Limited was founded in 1997 and is based in Wan Chai, Hong Kong. Beijing Enterprises Holdings Limited is a subsidiary of Beijing Enterprises Group (BVI) Company Limited.
Full BJINF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.